Synthesis, in Vitro Covalent Binding Evaluation, and Metabolism of 14C-Labeled Inhibitors of 11β-HSD1
- 30 September 2014
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 5 (11) , 1245-1250
Abstract
In this letter, we reported the design and synthesis of three potent, selective, and orally bioavailable 11β-HSD1 inhibitors labeled with 14C: AMG 456 (1), AM-6949 (2), and AM-7715 (3). We evaluated the covalent protein binding of the labeled inhibitors in human liver microsomes in vitro and assessed their potential bioactivation risk in humans. We then studied the in vitro mechanism of 2 in human hepatocytes and the formation of reactive intermediates. Our study results suggest that 1 and 3 have low potential for metabolic bioactivation in humans, while 2 has relatively high risk.Keywords
This publication has 23 references indexed in Scilit:
- Modulation of 11β-Hydroxysteroid Dehydrogenase (11βHSD) Activity Biomarkers and Pharmacokinetics of PF-00915275, a Selective 11βHSD1 InhibitorThe Journal of Clinical Endocrinology & Metabolism, 2008
- Tissue‐specific glucocorticoid excess in the metabolic syndrome: 11β‐HSD1 as a therapeutic targetDrug Development Research, 2006
- Cushing's syndromeThe Lancet, 2006
- Fatty Acid Regulation of Hepatic Gene TranscriptionThe Journal of Nutrition, 2005
- Inhibition of 11?-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?Expert Review of Cardiovascular Therapy, 2005
- 11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone actionJournal of Endocrinology, 2005
- 11β-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid ResponseEndocrine Reviews, 2004
- Novel Adipose Tissue–Mediated Resistance to Diet-Induced Visceral Obesity in 11β-Hydroxysteroid Dehydrogenase Type 1–Deficient MiceDiabetes, 2004
- Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11β-Hydroxysteroid Dehydrogenase Type 1Journal of Medicinal Chemistry, 2002
- A Transgenic Model of Visceral Obesity and the Metabolic SyndromeScience, 2001